Sviluppa antibody-drug conjugates ultra-stabili per tumori solidi con la piattaforma P5.
| Date | Round | Amount |
|---|---|---|
| Oct 2025 | Series C Tubulis closed a €308 million Series C led by Venrock Healthcare Capital Partners, the largest ever for a European biotech at this stage. | $357M |